Hycamtin

Hycamtan is a prescription tablet that contains the chemotherapy agent topotecan. It is supplied in oral tablet form and marketed in the European Union. As a topoisomerase I inhibitor, Hycamtan belongs to the antineoplastic drug class and is used under medical supervision for certain solid tumours. The product is prescription‑only and not a controlled substance, intended for adult patients and administered according to oncologist guidance.

Hycamtan (topotecan) is prescribed for the treatment of malignant neoplasms that are responsive to topoisomerase I inhibition, particularly when disease is advanced, recurrent, or not amenable to other standard chemotherapies.

- Ovarian cancer (including recurrent disease). - Small cell lung cancer (as part of combination therapy). - Cervical cancer (advanced or metastatic). - Other solid tumours where topotecan has demonstrated activity (e.g., certain gastrointestinal cancers). - Oropharyngeal cancer (selected cases). - Refractory solid tumours where other regimens have failed.

Adverse reactions to Hycamtan vary in frequency and severity, reflecting its cytotoxic activity.

Common: - Decreased white blood cell count (neutropenia), which may increase infection risk. - Nausea and vomiting, often managed with anti‑emetics. - Diarrhea, ranging from mild to moderate severity. - Fatigue or weakness, commonly reported during treatment cycles. - Anemia (low red blood cell count), leading to reduced oxygen carrying capacity. - Alopecia (hair loss), typically reversible after therapy ends. - Decreased appetite, which can affect nutritional intake.

Serious: - Severe infection due to neutropenia, which can be life‑threatening. - Significant bleeding from low platelet count, increasing risk of hemorrhage. - Acute renal impairment, potentially requiring dose adjustment. - Severe allergic reaction (anaphylaxis), presenting with rash, swelling, and respiratory distress. - Cardiac arrhythmias, including tachycardia or bradycardia. - Liver enzyme elevation leading to hepatitis, monitored via laboratory tests.

Before initiating Hycamtan, clinicians should evaluate several patient‑specific factors to minimize risk and ensure appropriate monitoring.

- Baseline complete blood count to assess marrow function. - Assessment of renal and hepatic function for dose considerations. - Pregnancy contraindication; women of childbearing potential must use effective contraception. - Caution in patients with pre‑existing infections or immunosuppression. - Monitor for signs of severe myelosuppression during each treatment cycle. - Evaluate cardiac history if prior arrhythmias were present. - Review concomitant medications that may affect bone‑marrow toxicity. - Inform patients about the potential for hair loss and advise on supportive care measures.

Hycamtan may interact with other agents that influence its metabolism, excretion, or bone‑marrow toxicity.

Avoid: - Strong CYP3A4 inducers, such as rifampin, which can reduce topotecan exposure. - Concurrent use of other myelosuppressive chemotherapy agents without dose adjustment. - Concurrent use of live vaccines, due to immunosuppression risk.

Use with caution: - Antiemetics containing metoclopramide, which may affect gastrointestinal motility. - Nephrotoxic drugs (e.g., cisplatin) that could exacerbate renal impairment. - Drugs that prolong QT interval, increasing cardiac risk. - High‑dose corticosteroids, which may mask infection signs. - Antifungal agents like fluconazole that can alter topotecan clearance. These interactions can modify drug levels or increase toxicity, so careful review of the medication list is essential.